Perrigo Company plc (NYSE:PRGO) Shares Acquired by Sei Investments Co.

Sei Investments Co. lifted its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 33.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 338,045 shares of the company’s stock after acquiring an additional 83,957 shares during the period. Sei Investments Co. owned approximately 0.25% of Perrigo worth $8,681,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Central Pacific Bank Trust Division purchased a new stake in Perrigo during the 1st quarter worth approximately $48,000. Parallel Advisors LLC lifted its stake in shares of Perrigo by 69.1% during the fourth quarter. Parallel Advisors LLC now owns 2,009 shares of the company’s stock worth $65,000 after buying an additional 821 shares during the period. TFC Financial Management Inc. grew its holdings in shares of Perrigo by 39.7% during the first quarter. TFC Financial Management Inc. now owns 2,462 shares of the company’s stock valued at $79,000 after buying an additional 700 shares during the last quarter. Beach Investment Counsel Inc. PA acquired a new position in shares of Perrigo in the 2nd quarter valued at $72,000. Finally, Voisard Asset Management Group Inc. raised its stake in Perrigo by 520.0% in the 2nd quarter. Voisard Asset Management Group Inc. now owns 4,650 shares of the company’s stock worth $119,000 after acquiring an additional 3,900 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Insider Buying and Selling at Perrigo

In other news, Director Katherine C. Doyle sold 8,954 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $27.30, for a total transaction of $244,444.20. Following the completion of the transaction, the director now directly owns 6,009 shares of the company’s stock, valued at approximately $164,045.70. The sale was disclosed in a filing with the SEC, which is available at this link. In other Perrigo news, EVP Svend Andersen sold 28,300 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $27.75, for a total transaction of $785,325.00. Following the completion of the transaction, the executive vice president now owns 73,553 shares of the company’s stock, valued at $2,041,095.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Katherine C. Doyle sold 8,954 shares of Perrigo stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $27.30, for a total value of $244,444.20. Following the completion of the sale, the director now directly owns 6,009 shares in the company, valued at $164,045.70. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,254 shares of company stock valued at $1,411,969. Company insiders own 0.70% of the company’s stock.

Perrigo Stock Up 0.1 %

Shares of PRGO stock opened at $25.65 on Friday. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 0.80. Perrigo Company plc has a twelve month low of $24.82 and a twelve month high of $34.60. The stock has a 50 day moving average of $27.78 and a 200 day moving average of $28.67. The stock has a market cap of $3.50 billion, a P/E ratio of -366.43 and a beta of 0.49.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Friday, August 2nd. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.13 billion. Perrigo had a negative net margin of 2.81% and a positive return on equity of 6.79%. The firm’s revenue was down 10.7% on a year-over-year basis. During the same quarter last year, the business earned $0.63 earnings per share. As a group, sell-side analysts expect that Perrigo Company plc will post 2.57 EPS for the current year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 17th. Shareholders of record on Friday, August 30th were given a dividend of $0.276 per share. The ex-dividend date of this dividend was Friday, August 30th. This represents a $1.10 dividend on an annualized basis and a yield of 4.30%. Perrigo’s dividend payout ratio is currently -1,571.43%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Jefferies Financial Group reissued a “hold” rating and issued a $30.00 price objective (down from $50.00) on shares of Perrigo in a report on Monday, September 23rd. Piper Sandler reduced their price target on shares of Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Finally, StockNews.com downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a report on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.00.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.